eflornithine


Also found in: Wikipedia.

eflornithine

 [ef-lor´nĭ-thēn″]
an inhibitor of the enzyme catalyzing the decarboxylation of ornithine; used topically as the hydrochloride salt to reduce unwanted facial hair in females. It has also been administered intravenously in treatment of African trypanosomiasis.

eflornithine

/ef·lor·ni·thine/ (DMFO) (ef-lor´nĭ-thēn″) an inhibitor of the enzyme catalyzing the decarboxylation of ornithine; used topically as the hydrochloride salt to reduce unwanted facial hair in females.

eflornithine

An antiprotozoal drug used to treat Pneumocystis carinii pneumonia and African TRYPANOSOMIASIS. The drug is on the WHO official list.

eflornithine

an antiprotozoal agent, used as the hydrochloride in trypanosomiasis and pneumocystiscarinii pneumonia.
References in periodicals archive ?
Our only eflornithine manufacturing facility is in Bangladesh, where it takes up two floors of a factory that also makes designer jeans.
Eflornithine cream is an FDA category C drug for use in pregnancy.
A quarter of the female patients in the study were treated with eflornithine hydrochloride, which inhibits hair cell growth, while fewer than 2% of males received this treatment.
Eflornithine hydrochloride (Vaniqa) may also help slow the hair growth on the face.
This combination consisted of sulindac, which is an older, established antiinflammatory medication, and [alpha]-difluoromethylornithine (DFMO), or eflornithine, a failed cancer-therapeutic drug that was later found to be a highly effective depilatory.
The currently available drugs for trypanosomiasis treatment include pentamidine (8), melarsoprol (9), and eflornithine (10).
Your GP may recommend a contraceptive pill that can suppress the hormones (androgens) that cause excess hair growth, or a cream - eflornithine - that prevents hair growth.
brucei gambiense, Pentamidine 4 mg/kg/d intramuscular or intravenous, for 7-10 days in haemolymphatic stage and Eflornithine 400 mg/kg/d in 4 doses for 14 days is recommended in patients with CNS involvement5,6.
1) Adverse reactions to eflornithine occur fairly frequently; about 25-50% of patients receiving eflornithine treatment will experience bone marrow toxicity and roughly 10% of patients experience gastrointestinal symptoms.